NOVELMED THERAPEUTICS
NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with large market potential and unmet medical need. We specialize in complement-based therapies. Over the last decade, we have generated pre-clinical dat... a and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies target non-orphan and orphan diseases and have the potential for a better safety and efficacy profile than currently marketed drugs
NOVELMED THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2003-01-01
Address:
Cleveland, Ohio, United States
Country:
United States
Website Url:
http://www.novelmed.com
Total Employee:
1+
Status:
Active
Contact:
4408666999
Total Funding:
1.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Euro Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Azaya Therapeutics
Azaya Therapeutics is a biotechnology company developing therapies for cancer and other serious medical conditions.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.novelmed.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "NovelMed Therapeutics"
Home - Novelmed
NovelMed is on track to develop game-changing therapies for patients with unmet needs, with our success in preclinical, pharmacological, toxicological, and clinical studies demonstrating the …See details»
About Us - Novelmed
NovelMed Therapeutics is a biotechnology company based in Ohio, specializing in the development of novel biologics to treat both non-rare diseases. We focus on targeting key aspects of the immune system that drive disease …See details»
NovelMed Therapeutics - Crunchbase Company Profile …
NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process.See details»
Partners/Investors - Novelmed
NovelMed is actively pursuing investments, partnerships, or acquisition opportunities to drive the advancement of its antibody therapy pipeline. Our lead candidates have successfully …See details»
NovelMed Company Profile - Office Locations, Competitors ... - Craft
NovelMed is a company developing anti-complement antibodies as a treatment for complement-mediated disorders. Its technology is capable of producing a proprietary pipeline of …See details»
NovelMed Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Established in 2003, the company focuses on being a clinical-stage biopharmaceutical entity with a commitment to innovation and the development of novel biologics for treating rare (orphan) …See details»
NovelMed Therapeutics - Funding, Financials, Valuation & Investors
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.See details»
NovelMed - LinkedIn
A promise to patients with complement-mediated rare diseases. | NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective …See details»
FDA grants orphan drug status to NovelMed’s PNH treatment
Apr 16, 2024 · NovelMed has announced the receipt of orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug, NM5072, for treating …See details»
NovelMed’s PNH antibody therapy NM8074 now called ruxoprubart
Jan 29, 2024 · NM8074, an investigational antibody therapy for paroxysmal nocturnal hemoglobinuria (PNH), will now be called ruxoprubart, its developer NovelMed has …See details»
Contact Us - Novelmed
About novelMed. NovelMed is actively seeking investments, partnerships, or acquisition opportunities to advance its pipeline of antibody therapies. Our lead candidates have …See details»
NovelMed Announces Interim Positive Results from Its Phase I …
Feb 21, 2022 · NovelMed is the first company to have invented and validated an anti-Bb antibody to treat chronic complement-mediated and complement-associated disorders. NovelMed is …See details»
NovelMed's Complement Alternative Pathway Specific Anti-Bb …
Jan 31, 2022 · NovelMed is a clinical-stage biopharmaceutical company committed to innovating and developing biologics to treat rare diseases caused by the overactivation of the …See details»
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a …
Mar 6, 2023 · NovelMed is seeking to license the Anti-Properdin program to advance the development of NM3086 for Wet-AMA, Dry-AMD, GA, and rare ocular diseases.See details»
R&D Strategy - novelmed.com
With over 80 issued patents, NovelMed has established itself as a leader in rapid drug development, moving from concept to clinic in just three years. This accelerated progress is …See details»
NovelMed Phase I Clinical Trial Shows Inhibition of the
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker …See details»
NovelMed Receives FDA Orphan Drug Designation for Treating …
NovelMed recently announced the US FDA has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the treatment of …See details»
Product Pipeline - novelmed.com
We are expanding our pipeline to include new antibody therapies for both rare and non-rare diseases, focusing on identifying rare diseases with dysregulated complement system. Our …See details»
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative ...
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker …See details»
News - NovelMed Therapeutics
NovelMed is actively seeking investments, partnerships, or acquisition opportunities to advance its pipeline of antibody therapies. Our lead candidates have successfully completed clinical trials …See details»